CAY10678

CAS No. 1268709-57-4

CAY10678( —— )

Catalog No. M35031 CAS No. 1268709-57-4

CAY10678 is an mPGES-1 inhibitor that inhibits PD-1.CAY10678 reduces collagen deposition and T-cell depletion, and may be used to study melanoma.CASHIPS

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 117 In Stock
10MG 180 In Stock
25MG 353 In Stock
50MG 523 In Stock
100MG 737 In Stock
200MG Get Quote In Stock
500MG 1516 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CAY10678
  • Note
    Research use only, not for human use.
  • Brief Description
    CAY10678 is an mPGES-1 inhibitor that inhibits PD-1.CAY10678 reduces collagen deposition and T-cell depletion, and may be used to study melanoma.CASHIPS
  • Description
    CAY10678 is an mPGES-1 inhibitor that inhibits PD-1.CAY10678 reduces collagen deposition and T-cell depletion, and may be used to study melanoma.CASHIPS
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Immunology/Inflammation
  • Target
    PD-1/PD-L1
  • Recptor
    PD-1/PD-L1 | Prostaglandin Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1268709-57-4
  • Formula Weight
    382.54
  • Molecular Formula
    C23H34N4O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(NC1CCCC1)C2CCN(C3=NC=4C=C(C(=CC4N3C(C)C)C)C)CC2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • BMS-8

    BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.

  • ARB-272572 hydrochlo...

    ARB-272572 hydrochloride is a small molecule PD-L1 inhibitor with an IC50 value of 400 pM for PD-1/PD-L1 HTRF.ARB-272572 hydrochloride inhibits PD-1/PD-L1 cell signaling by inducing homologous interactions with PD-L1 proteins.

  • Camrelizumab

    Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity directed against PD-1, binding PD-1 with an affinity of up to 3 nM and inhibiting PD-1/PD-L1 with an IC50 of 0.70 nM.